Human CCL22/MDC Antibody Summary
Accession # O00626
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Chemotaxis Induced by CCL22/MDC and Neutralization by Human CCL22/MDC Antibody. Recombinant Human CCL22/MDC (Catalog # 336-MD) chemoattracts the BaF3 mouse pro-B cell line transfected with human CCR4 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL22/MDC (0.03 µg/mL) is neutralized (green line) by increasing concentrations of Chicken Anti-Human CCL22/MDC Antigen Affinity-purified Polyclonal Antibody (Catalog # AF336). The ND50 is typically 0.4-2.0 µg/mL.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
CCL22, also named stimulated T cell chemotactic protein (STCP-1), is a CC chemokine initially isolated from clones of monocyte-derived macrophages. Human CCL22 cDNA encodes a precursor protein of 93 amino acid residues with a 24 amino acid residue predicted signal peptide that is cleaved to yield a 69 amino acid residue mature 8 kDa protein. At the amino acid sequence level, CCL22 shows less than 35% identity to other CC chemokine family members. Human CCL22 is expressed in dendritic cells, macrophages and activated monocytes. In addition, CCL22 expression is also detected in the tissues of thymus, lymph node and appendix. The gene for human CCL22 has been mapped to chromosome 16 rather than chromosome 17 where the genes for many human CC chemokines are clustered. Recombinant or chemically synthesized mature CCL22 has been shown to induce chemotaxis or Ca2+ mobilization in dendritic cells, IL-2 activated NK cells, and activated T lymphocytes. A CD8+ T lymphocyte-derived secreted soluble activity that suppresses infection by primary non-syncytium-inducing and syncytium-inducing HIV-1 isolates and the T cell line-adapted isolate HIV-1IIIB, has been identified as CCL22. Based on amino-terminal sequence analysis, the major CD8+ T lymphocyte-derived CCL22 protein yielded an amino-terminal sequence of YGANM, which is two amino acid residues shorter than the predicted mature CCL22. The difference in potency between the two mature CCL22 isoforms has not been determined.
Citation for Human CCL22/MDC Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
Expression and regulation of chemokines in murine and human type 1 diabetes.
Authors: Sarkar SA, Lee CE, Victorino F, Nguyen TT, Walters JA, Burrack A, Eberlein J, Hildemann SK, Homann D
Sample Types: Whole Cells
Applications: Flow Cytometry
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human CCL22/MDC Antibody
Average Rating: 3 (Based on 1 Review)
Have you used Human CCL22/MDC Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
We used this antibody in an in-house ELISA along with mAb (336) and protein standard (336-MD) to quantify CCL22 in human serum and plasma. This combination could not detect CCL22 in our samples but generated a good standard curve.